Research Calls I
-
Upgrades:
- Air Products (APD) upgraded to Buy from Neutral at UBS; tgt $375
- Amylyx Pharmaceuticals (AMLX) upgraded to Outperform from Neutral at Robert W. Baird; tgt raised to $11
- Autolus Therapeutics (AUTL) upgraded to Buy from Neutral at Goldman; tgt raised to $7.60
- Bright Horizons (BFAM) upgraded to Outperform from Market Perform at BMO Capital Markets; tgt lowered to $125
- CVS Health (CVS) upgraded to Overweight from Equal Weight at Wells Fargo; tgt raised to $66
- Hewlett Packard Enterprise (HPE) upgraded to Strong Buy from Outperform at Raymond James; tgt raised to $29
- MBIA (MBI) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt raised to $9
- Moderna (MRNA) upgraded to Buy from Hold at HSBC Securities; tgt $58
- Monolithic Power (MPWR) upgraded to Buy from Hold at Loop Capital; tgt $660
- Robinhood Markets (HOOD) upgraded to Buy from Hold at Needham; tgt $40
- Roku (ROKU) upgraded to Outperform from Neutral at Robert W. Baird; tgt raised to $90
- United Fire Group (UFCS) upgraded to Neutral from Underweight at Piper Sandler; tgt raised to $26
-
Downgrades:
- Avis Budget (CAR) downgraded to Neutral from Buy at Northcoast
- Biogen (BIIB) downgraded to Hold from Buy at Needham
- Crane (CR) downgraded to Hold from Buy at Stifel; tgt $176
- Curtiss-Wright (CW) downgraded to Hold from Buy at Stifel; tgt $370
- EOG Resources (EOG) downgraded to Neutral from Overweight at Piper Sandler; tgt raised to $149
- ESAB Corp. (ESAB) downgraded to Hold from Buy at Stifel; tgt lowered to $130
- Eyenovia (EYEN) downgraded to Neutral from Buy at H.C. Wainwright; tgt lowered to $2
- FB Financial (FBK) downgraded to Market Perform from Outperform at Hovde Group; tgt $60
- Ingersoll-Rand (IR) downgraded to Hold from Buy at Stifel; tgt lowered to $107
- Liberty Global (LBTYA) downgraded to Neutral from Buy at UBS; tgt lowered to $13
- Matson (MATX) downgraded to Peer Perform from Outperform at Wolfe Research
- National Bank (NBHC) downgraded to Market Perform from Outperform at Hovde Group; tgt $55
- Parker-Hannifin (PH) downgraded to Hold from Buy at Stifel; tgt $691
- Pinnacle Finl (PNFP) downgraded to Market Perform from Outperform at Hovde Group; tgt $135
- Pinnacle West (PNW) downgraded to Equal Weight from Overweight at Barclays; tgt lowered to $91
- Redfin (RDFN) downgraded to Sell from Neutral at Goldman; tgt raised to $6.50
-
Others:
- Akero Therapeutics (AKRO) initiated with a Buy at Citigroup; tgt $65
- Astera Labs (ALAB) initiated with a Buy at Citigroup; tgt $120
- Capricor Therapeutics (CAPR) initiated with a Buy at JonesResearch
- enGene Holdings (ENGN) initiated with a Mkt Outperform at JMP Securities; tgt $18
- Erasca (ERAS) initiated with a Buy at Jefferies; tgt $6
- GATX (GATX) initiated with a Buy at Goldman; tgt $185
- Ingram Micro Holding Corp. (INGM) initiated with a Buy at Loop Capital; tgt $30
- Ingram Micro Holding Corp. (INGM) initiated with an Outperform at Raymond James; tgt $28
- Ingram Micro Holding Corp. (INGM) initiated with an Equal-Weight at Morgan Stanley; tgt $24
- Ingram Micro Holding Corp. (INGM) initiated with a Neutral at Exane BNP Paribas; tgt $25
- Ingram Micro Holding Corp. (INGM) initiated with a Buy at Stifel; tgt $28
- Ingram Micro Holding Corp. (INGM) initiated with a Buy at Deutsche Bank; tgt $26
- Ingram Micro Holding Corp. (INGM) initiated with a Buy at BofA Securities; tgt $30
- Ingram Micro Holding Corp. (INGM) initiated with an Outperform at RBC Capital Mkts; tgt $26
- Ingram Micro Holding Corp. (INGM) initiated with an In-line at Evercore ISI; tgt $27
- Ingram Micro Holding Corp. (INGM) initiated with a Buy at Jefferies; tgt $28
- Ingram Micro Holding Corp. (INGM) initiated with a Buy at Redburn Atlantic; tgt $30
- Korro Bio (KRRO) initiated with a Buy at JonesResearch
- Penguin Solutions (PENG) initiated with a Mkt Outperform at JMP Securities; tgt $23
- RXO, Inc. (RXO) resumed with a Neutral at Goldman; tgt $29
- TechnipFMC (FTI) initiated with an Outperform at RBC Capital Mkts; tgt $37
- Trinity Industries (TRN) initiated with a Neutral at Goldman; tgt $39
- VYNE Therapeutics (VYNE) initiated with a Buy at BTIG Research; tgt $8